Twist Bioscience

Synthetic DNA for Health & Sustainability

Founded 2013

South San Francisco, United States 1317 employees IPO Total: $943.10M Biotechnology, Health Care +1

General Information

Company Name Twist Bioscience

Founded Year 2013

Location

South San Francisco, United States

Employees 1317

Industries Biotechnology, Health Care, Life Sciences

Funding Stage IPO

Business Model B2B, D2C, SaaS

Revenue Model Product Sales, Service Fee, Licensing

Offices as of Oct 2026

South San Francisco, United States San Francisco, United States Tel Aviv, Israel Carlsbad, United States Wilsonville, United States Quincy, United States

Social

BounceWatch is an independent company data service, not affiliated with Twist Bioscience. To contact Twist Bioscience, visit twistbioscience.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Twist Bioscience compare?

A PDF of Twist Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Twist Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 21, 2026

Twist Bioscience participated in the Festival of Biologics in Basel, Switzerland, where their team engaged with attendees and Emilie Madura delivered a presentation.

Major Customer Win Oct 20, 2026

Twist Bioscience secured a major customer win by providing control material to the Nebraska Public Health Laboratory, enabling them to develop a hantavirus assay in 72 hours.

New Partnership Oct 19, 2026

Twist Bioscience partnered with San Mateo County Parks to remove invasive species at Pillar Point Bluffs, contributing to local environmental conservation.

In The News Oct 17, 2026

Featured on Investing.com India: Form 144 Twist Bioscience Corp For: 17 October By Investing.com

In The News Oct 17, 2026

Featured on Yahoo! Finance Canada: Twist Bioscience Corporation (TWST) Options Chain - Yahoo Finance

Growth Metrics Oct 17, 2026

Twist Bioscience reported impressive growth, having grown for 14 quarters in a row.

+3 more signals in last 30 days

Get alerts when Twist Bioscience shows new signals

AI Insight

Bounce Watch AI

2 months ago

Twist Bioscience has recently secured significant post-IPO equity funding, including a $250 million round, underscoring strong investor confidence. Concurrently, the company's crucial role in independently validating Anthropic's AI-designed protein binders positions it at the forefront of the rapidly evolving AI drug discovery and synthetic biology fields. This highlights Twist's essential capability in providing high-precision, scalable synthetic DNA and protein services, accelerating groundbreaking research for its biopharma and biotech clientele.

Signal Types

Funding Strategic Alliance Product Validation

Strategic Labels

AI Drug Discovery Enabler Platform Validation Capital Infusion

Next Move: Expansion

Impact: 9/10

Ideal For: Public Market Investors — Synthetic Biology & AI Biotech

About Twist Bioscience

Twist Bioscience, a leading force in synthetic biology, is based in South San Francisco, California. Founded in 2013, the company's mission—a resonant "Synthetic DNA for Health & Sustainability"—is to empower life science research across diverse fields such as medicine, agriculture, and industrial chemicals.

At its core, Twist Bioscience leverages a proprietary silicon-based manufacturing process to deliver high-precision and high-throughput synthetic DNA. This unparalleled capability allows researchers to drive forward sustainability and health innovations by enhancing the quality and speed of DNA synthesis and sequencing.

The company's value proposition is underscored by a recent $250.00M Post Ipo Equity investment dated 01 August 2026. This capital infusion positions Twist Bioscience robustly in the Biotechnology and Life Sciences sector as it continues to overcome existing efficiency barriers. Without publicly disclosed investors for the latest funding, the company maintains a strategic ambiguity in its investment relations.

Business keywords: Synthetic Biology, DNA Synthesis, Gene Synthesis, CRISPR, Drug Discovery, Next Gen Sequencing, DNA Data Storage, Variant Libraries, DNA Sequencing, Exome Sequencing, Target Enrichment, Oligonucleotides, Life Sciences, Biopharma Services

Services & Products

Gene Synthesis

Antibody Production and Characterization

Library Preparation Solutions

Variant Library Development

DNA Synthesis on Silicon Platform

Target Customers

Biotechnology Companies Cancer Researchers Pharmaceutical Companies Agricultural Biotechnology Firms Infectious Disease Research Labs Genomic Research Institutions AI Drug Discovery Researchers

Funding Rounds & Investors (14)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$250.00M	-		01 Aug 2026
Post-IPO Equity	Undisclosed	1	Maxi Investments	01 May 2026
Post-IPO Equity	$250.00M	-		01 Feb 2022
Post-IPO Equity	$50.00M	-		01 Jan 2020
IPO	$70.00M	-		01 Oct 2018
IPO	$70.00M	-		01 Oct 2018
Late VC	$50.00M	-		01 Apr 2018
Series E	$27.00M	4	Biomatics Capital Partners, 3W Partners +2	01 Jun 2017
Series D	$33.00M	2	Asset Management Ventures, Dentsu Ventures	01 Mar 2017
Series D	$61.00M	10	Asset Management Ventures, Arch Venture Partners +8	01 Jan 2016

View All 14 Funding Rounds

Latest News

View All

Form 144 Twist Bioscience Corp For: 17 October By Investing.com

Investing.com India Oct 17, 2026

Twist Bioscience Corporation (TWST) Options Chain - Yahoo Finance

Yahoo! Finance Canada Oct 17, 2026

Where Twist Bioscience Goes After A 370% Climb

Simply Wall Street Oct 16, 2026

Google DeepMind’s watermarked AI proteins still work in the lab

Thenextweb Oct 01, 2026

Anthropic says Claude designed working protein binders, and beat human experts on some

Thenextweb Aug 19, 2026

OpenAI and Anthropic Sign Letter to Prevent AI-Developed Biological Weapons

Wired Jun 04, 2026

Twist Bioscience Alternatives & Competitors

View All Alternatives

Twist Bioscience vs

Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees

Biotechnology, Health Care

Compare Twist Bioscience vs Synbio Technologies

Twist Bioscience vs

Eurofins Genomics Americas United States

Honoring the Science of Life

57 employees

Biotechnology, Life Sciences

Compare Twist Bioscience vs Eurofins Genomics Americas

Twist Bioscience vs

Camena Bioscience United Kingdom

Unlocking access to genes with unparalleled accuracy

Series A

23 employees

Biotechnology, Health Care

Compare Twist Bioscience vs Camena Bioscience

Also compare with:

Molecular Assemblies, Inc. View all alternatives

FAQ About Twist Bioscience

Synthetic DNA for Health & Sustainability

Twist Bioscience was founded in 2013.

Twist Bioscience is headquartered in South San Francisco, United States. As of Oct 2026, it also has offices in San Francisco, United States, Tel Aviv, Israel, Carlsbad, United States, Wilsonville, United States and Quincy, United States.

Twist Bioscience operates in Biotechnology, Health Care and Life Sciences. Its work centres on Synthetic Biology, DNA Synthesis, Gene Synthesis and CRISPR. Its customers include Biotechnology Companies, Cancer Researchers and Pharmaceutical Companies.

Twist Bioscience has a B2B, D2C and SaaS business model. Its revenue comes from Product Sales, Service Fee and Licensing.

Twist Bioscience has approximately 1317 employees.

Twist Bioscience has completed 14 funding rounds, raising a total of $943.10M. The latest funding stage is IPO.

Twist Bioscience offers: Gene Synthesis, Antibody Production and Characterization, Library Preparation Solutions, Variant Library Development, DNA Synthesis on Silicon Platform.

Top alternatives and competitors to Twist Bioscience include Synbio Technologies, Eurofins Genomics Americas, Camena Bioscience, Telesis Bio, New England Biolabs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Twist Bioscience and Synbio Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Twist Bioscience, https://bouncewatch.com/company/twist-bioscience, updated 11 October 2026. When citing, please name BounceWatch and link this page.

Twist Bioscience

General Information

Discover More

What changed at Twist Bioscience recently?

AI Insight

About Twist Bioscience

Services & Products

Target Customers

Funding Rounds & Investors (14)

Latest News

Twist Bioscience Alternatives & Competitors

FAQ About Twist Bioscience